Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report report published on Monday morning, Benzinga reports. They currently have a $14.00 price objective on the stock.

Coya Therapeutics Stock Down 2.6 %

COYA stock opened at $8.38 on Monday. The stock has a market capitalization of $122.35 million, a P/E ratio of -10.74 and a beta of 0.80. The firm has a 50-day simple moving average of $9.20 and a 200-day simple moving average of $7.18. Coya Therapeutics has a 52 week low of $3.21 and a 52 week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, March 19th. The company reported $0.15 earnings per share for the quarter. The business had revenue of $6.00 million for the quarter.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of COYA. CM Management LLC boosted its holdings in Coya Therapeutics by 66.7% in the 3rd quarter. CM Management LLC now owns 100,000 shares of the company’s stock valued at $384,000 after purchasing an additional 40,000 shares during the last quarter. AIGH Capital Management LLC boosted its holdings in Coya Therapeutics by 92.6% in the 4th quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock valued at $7,381,000 after purchasing an additional 496,183 shares during the last quarter. Finally, Greenlight Capital Inc. boosted its holdings in Coya Therapeutics by 172.2% in the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after purchasing an additional 805,959 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.